Alan H. Bryce, MD

Experts weigh real‑world evidence for prostate cancer drug comparisons, explaining bias risks, data quality, and how it complements trials.

Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.

Experts weigh real-world factors and ARASENS insights, comparing triplet therapy gains, toxicity, and when to pause treatment.

Experts debate real‑world factors, ARASENS triplet benefits, and when to pause prostate cancer therapy after deep PSA response.

Learn practical monitoring schedules for modern prostate cancer therapies, from early toxicity checks to long-term heart, bone and exercise care.

Learn how clinicians monitor ARPI therapy in metastatic prostate cancer—early monthly labs, then spaced visits, plus heart, bone and exercise care.

How clinicians manage comorbidities and polypharmacy, navigating drug‑drug interactions with ARPIs, statins and anticoagulants using team care.

Experts highlight cognitive decline and fall risk in older prostate cancer patients on ADT/ARPI, urging tailored drug selection and simple in-clinic screening.

Experts reveal how disease volume, symptoms, visceral spread and pathology steer androgen inhibitor choices and SBRT add-ons in mCSPC.

Clinicians weigh comorbidities and polypharmacy, checking statin and anticoagulant interactions to choose the safest ARPI hormone therapy.

Learn how disease burden, relapse history, patient preferences, cognition, and support systems guide personalized treatment intensification in mCSPC.

Tailor MCSPC treatment by weighing disease burden, timing of recurrence, patient goals, cognition, and family support before intensifying therapy.

David Morris, MD, FACS, and Alan H. Bryce, MD, discuss the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

Experts weigh PSMA PET’s impact on metastatic prostate cancer therapy, balancing doublets, triplets and de‑intensification for low‑volume disease.

Clinical trials show adding upfront therapies to ADT for metastatic hormone-sensitive prostate cancer boosts survival and quality of life, making ADT alone outdated.

Modern prostate cancer care treats survivorship as central—favoring active surveillance when appropriate and prioritizing long-term quality of life.

Explore how comorbidities and polypharmacy shape treatment choices in metastatic prostate cancer, guiding safe therapy intensification with multidisciplinary care.

This discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy intensification with overall health status, medication interactions, and long-term safety when developing individualized treatment plans.

The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and often have multiple comorbidities, making long-term tolerability and quality of life key considerations in treatment planning.

Alan H. Bryce, MD, discusses the implications of the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

Alan H. Bryce, MD, discusses treatment comparisons of ARPI efficacy according to disease volume and timing of metastasis development in mHSPC.

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.